The Federal Drug Agency Gives Its Approval towards Novel Oral Anti-Platelet Agent: Ticagrelor
The Federal Drug Agency (FDA) has given its approval of the use of ticagrelor tablets in order to reduce the rate of myocardial infarction (heart attack) and cardiovascular death among adult patients that have been diagnosed with acute coronary syndrome (ACS).
The drug Ticagrelor is a new form of oral anti-platelet in medicine and is has been showed to lower the pace of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS), Non ST elevation myocardial infarction (NSTEMI), unstable angina (UA) and even ST elevation myocardial infarction (STEMI).
This drug has also indicated that it can lower the rate of joint end point of cardiovascular death, myocardial infarction and stroke when tested in relation to clopidogrel. This variation in the success rate of the treatments was clearly demonstrated by myocardial infarction and cardiovascular death, stroke showed no variation. In patients that were given treatment with percutaneous coronary intervention, an artery opening method, it was discovered that the drug Ticagrelor causes a reduction in the rate of stent thrombosis. This medication has also been researched in acute coronary syndrome in conjunction with aspirin. Taking aspirin in dosages above one hundred milligrams was shown to have an adverse effect on the effectiveness of ticagrelor. Therefore it is highly advisable that patients using ticagrelor should try by all means to avoid taking aspirin in doses greater than one hundred milligrams, on a daily basis.
Doctor Randy Vogenberg, PHD, told 'Drug Topics' that history has learnt from the controversy that has occurred in stent research during past years. He went on to say that patients suffering from CHD (Coronary Heart Disease) are not easy to monitor and regulate on varied prophylactic regimens or mechanical methods. Professor Randy Vogenberg is the executive director of the Jefferson School Population Health in Philadelphia's Biologic Access and Finance Program. He is also the principal at the institute Sharon based Institute for Integrated Healthcare.
Doctor Vogenberg went on to say that Brilinta is representative of an additional challenge in using medical therapies to aid in Acute Coronary Syndrome. He further states that what this implicates for regulated care clinicians and organisations is greater caution during patient medication therapy selection procedures in addition to perseverance if the required clinical results are to be obtained in 'real world' patient populations. Vogenberg is the main author of the publication 'Pharmacy Benefits: Management and Benefit Design, this publication is currently published by the IFEBP.
The CEO of AstraZeneca, said in a press release that he believes that the approval of ticagrelor by the Federal Drug Agency is very good news for patients. He went on to say that with an excess of one million people currently affected with Acute Coronary Syndrome annually in America that physicians are able to produce more efficient treatment options other than clopidogrel, is very helpful in the reduction of the rate of cardiovascular death and heart attack in patients.
With the recent approval of clopidogrel within America, AstraZeneca can now start working in collaboration with protocol committees, government, hospital formularies and regulated care reimbursement organisations to bring this novel drug to patients.
The Fedaral Drug Agency Based its approval on tests conducted in the Platelet Inhibition and Patient Outcomes study. This study made comparisons between the treatment of patients with clopidogrel and tricagrelor among eighteen thousand six hundred and twenty four patients of Acute Coronary Syndrome Nationwide.